Mr. Alles is the former Chairman and Chief Executive Officer of Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company (BMS). In his 16-year tenure at Celgene, Mr. Alles led the expansion of the company from a US-based organization with less than 500 employees into a global enterprise serving patients in more than 50 countries with 8,800 employees. He held a series of commercial and leadership roles of escalating responsibility, consistently delivering industry-leading financial performance. He led teams that completed several multibillion-dollar company or asset acquisitions, built a diverse suite of globally marketed medicines and a pipeline of high-potential therapeutics for cancer and serious inflammatory diseases, all of which ultimately led to the $74 billion acquisition of Celgene by BMS.
Merry Christmas and a Happy New Year!!!
Recent SYRS News
- Syros to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 01:00:00 PM
- Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 • Business Wire • 05/07/2024 11:00:00 AM
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression • Business Wire • 04/09/2024 11:00:00 AM
- Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2024 08:30:00 PM
- Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update • Business Wire • 03/27/2024 11:30:00 AM
- U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading • IH Market News • 03/27/2024 10:57:08 AM
- Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial • Business Wire • 03/25/2024 11:00:00 AM
- Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 • Business Wire • 03/20/2024 11:00:00 AM
- Syros to Participate in TD Cowen 44th Annual Health Care Conference • Business Wire • 02/27/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:56:21 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:22:30 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:02:26 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 11:59:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:06:32 PM
- Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene • Business Wire • 01/08/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/02/2024 09:15:13 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/26/2023 10:19:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:59:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/19/2023 09:53:10 PM
- Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants • Business Wire • 12/19/2023 12:27:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 09:24:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/12/2023 09:12:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:23:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/06/2023 09:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 12:05:32 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM